Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1964 2
1967 1
1968 2
1969 2
1970 5
1971 6
1972 5
1973 7
1974 4
1975 11
1976 11
1977 7
1978 10
1979 7
1980 11
1981 7
1982 17
1983 18
1984 12
1985 24
1986 28
1987 32
1988 29
1989 31
1990 39
1991 44
1992 44
1993 63
1994 62
1995 56
1996 80
1997 79
1998 82
1999 99
2000 76
2001 77
2002 75
2003 102
2004 112
2005 105
2006 111
2007 106
2008 106
2009 120
2010 123
2011 101
2012 116
2013 144
2014 169
2015 172
2016 137
2017 148
2018 140
2019 163
2020 141
2021 89
Text availability
Article attribute
Article type
Publication date

Search Results

3,298 results
Results by year
Filters applied: . Clear all
Page 1
Search for hepatic immunosuppresive factor instead (2 results)
Gastrointestinal system involvement in systemic lupus erythematosus.
Li Z, Xu D, Wang Z, Wang Y, Zhang S, Li M, Zeng X. Li Z, et al. Lupus. 2017 Oct;26(11):1127-1138. doi: 10.1177/0961203317707825. Epub 2017 May 19. Lupus. 2017. PMID: 28523968 Review.
This study aims to clarify clinical characteristics, diagnosis and treatment of the four major SLE-related GI system complications: protein-losing enteropathy (PLE), intestinal pseudo-obstruction (IPO), hepatic involvement and pancreatitis. It is a systematic review using …
This study aims to clarify clinical characteristics, diagnosis and treatment of the four major SLE-related GI system complications: protein- …
Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity.
Bentata Y. Bentata Y. Artif Organs. 2020 Feb;44(2):140-152. doi: 10.1111/aor.13551. Epub 2019 Sep 4. Artif Organs. 2020. PMID: 31386765 Review.
Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of transplantation in the 1990s, is the cornerstone of most immunosuppressive regimens in solid organ transplantation. Its use has revolutionized the future of kidney transplantation (KT) and has been …
Tacrolimus (or FK506), a calcineurin inhibitor (CNI) introduced in field of transplantation in the 1990s, is the cornerstone of most immu
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
Staatz CE, Tett SE. Staatz CE, et al. Clin Pharmacokinet. 2004;43(10):623-53. doi: 10.2165/00003088-200443100-00001. Clin Pharmacokinet. 2004. PMID: 15244495 Review.
Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepatitis C status, time after transplantation, patient age, donor liver characteristics, recipient race, haematocrit and albumin concentrations,
Factors reported to influence the pharmacokinetics of tacrolimus include the patient group studied, hepatic dysfunction, hepat
Safety of Systemic Agents for the Treatment of Pediatric Psoriasis.
Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS; Psoriasis Investigator Group (PsIG) of the Pediatric Dermatology Research Alliance and the European Working Group on Pediatric Psoriasis (EWGPP). Bronckers IMGJ, et al. JAMA Dermatol. 2017 Nov 1;153(11):1147-1157. doi: 10.1001/jamadermatol.2017.3029. JAMA Dermatol. 2017. PMID: 28903160 Free PMC article.
Injection site reactions occurred in 20 of 106 patients (18.9%) treated with tumor necrosis factor inhibitors, but did not lead to discontinuation of treatment. ...A prospective registry is needed to track the long-term risks of systemic agents for pediatric psorias …
Injection site reactions occurred in 20 of 106 patients (18.9%) treated with tumor necrosis factor inhibitors, but did not lead to di …
Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM, Fitzhugh CD, Weitzel RP, Link ME, Coles WA, Zhao X, Rodgers GP, Powell JD, Tisdale JF. Hsieh MM, et al. JAMA. 2014 Jul 2;312(1):48-56. doi: 10.1001/jama.2014.7192. JAMA. 2014. PMID: 25058217 Free PMC article. Clinical Trial.
Fifteen engrafted patients discontinued immunosuppression medication with continued stable donor chimerism and no graft-vs-host disease. ...Further accrual and follow-up are required to assess longer-term clinical outcomes, adverse events, and transplant toleranc
Fifteen engrafted patients discontinued immunosuppression medication with continued stable donor chimerism and no graft-vs-host
Autoimmune hepatitis.
Longhi MS, Mieli-Vergani G, Vergani D. Longhi MS, et al. Curr Pediatr Rev. 2014;10(4):268-74. doi: 10.2174/1573396310666141114230147. Curr Pediatr Rev. 2014. PMID: 25403636 Review.
Though the exact mechanism leading to loss of immune-tolerance in AIH is still unclear, recent evidence has pointed to a numerical and functional defect of CD4(pos)CD25(pos) regulatory T-cells as a factor permitting autoaggressive CD4 and CD8 T-cells to react …
Though the exact mechanism leading to loss of immune-tolerance in AIH is still unclear, recent evidence has pointed to a numer …
Drug-induced hepatic steatosis.
Amacher DE, Chalasani N. Amacher DE, et al. Semin Liver Dis. 2014 May;34(2):205-14. doi: 10.1055/s-0034-1375960. Epub 2014 May 31. Semin Liver Dis. 2014. PMID: 24879984 Review.
Drug-induced hepatic steatosis is generally a chronic but reversible affliction and may involve drug accumulation in the liver. ...Commonly used medications associated with DIHS include amiodarone, valproate, tamoxifen, methotrexate, and some chemotherapeutic and antiretro …
Drug-induced hepatic steatosis is generally a chronic but reversible affliction and may involve drug accumulation in the liver. ...Co …
Autoimmune hepatitis.
Lohse AW, Mieli-Vergani G. Lohse AW, et al. J Hepatol. 2011 Jul;55(1):171-82. doi: 10.1016/j.jhep.2010.12.012. Epub 2010 Dec 15. J Hepatol. 2011. PMID: 21167232 Free article. Review.
The clinical spectrum is very wide, ranging from subclinical non-progressive disease to fulminant hepatic failure. Diagnostic criteria based on elevation of IgG, demonstration of characteristic autoantibodies, and histological features of hepatitis in the absence of viral …
The clinical spectrum is very wide, ranging from subclinical non-progressive disease to fulminant hepatic failure. Diagnostic criteri …
Induction Phase of Spontaneous Liver Transplant Tolerance.
McCaughan GW, Bowen DG, Bertolino PJ. McCaughan GW, et al. Front Immunol. 2020 Sep 11;11:1908. doi: 10.3389/fimmu.2020.01908. eCollection 2020. Front Immunol. 2020. PMID: 33013840 Free PMC article. Review.
Early experiments in liver transplantation demonstrated that in animal models, hepatic allografts could be accepted across MHC-mismatch without the use of immunosuppression, and that transplantation of livers from the same donor was capable of inducing tolerance
Early experiments in liver transplantation demonstrated that in animal models, hepatic allografts could be accepted across MHC-mismat …
Hepatic immunosuppressive effects of systemically administered novel dextran-methylprednisolone prodrugs with peptide linkers in rats.
Shaik IH, Agarwal HK, Parang K, Mehvar R. Shaik IH, et al. J Pharm Sci. 2012 Oct;101(10):4003-12. doi: 10.1002/jps.23274. Epub 2012 Jul 24. J Pharm Sci. 2012. PMID: 22829462 Free PMC article.
The hepatic immunosuppressive activities of two novel dextran prodrugs of methylprednisolone (MP) containing one (DMP1) or five (DMP5) amino acids as linkers were studied in rats. At various times (0-2 weeks) after intravenous administration of single 5 mg/kg (MP eq …
The hepatic immunosuppressive activities of two novel dextran prodrugs of methylprednisolone (MP) containing one (DMP1) or fiv …
3,298 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page